Table 1.
Distribution of patient characteristics for the analysis dataset
| Characteristic | PPMI-PD | PPMI-Genetic Cohort PD | PPMI-Genetic Registry PD | ICICLE-PD |
|---|---|---|---|---|
| Sample size (%) | 423 (49.1) | 114 (13.2) | 110 (12.8) | 215 (24.9) |
| Gender | ||||
| Male (%) | 277 (32.10) | 46 (5.34) | 50 (5.80) | 136 (15.80) |
| Female (%) | 146 (16.90) | 68 (7.89) | 60 (6.96) | 79 (9.16) |
| Baseline age (year) | ||||
| Median (range) | 62 (33,84) | 62 (32,85) | 72 (38,88) | 66 (35, 87) |
| Missing (%) | 0 (0.0) | 0 (0.0) | 2 (0.23) | 0 (0.0) |
| Baseline body weight (kg) | ||||
| Median (range) | 80.7 (40.8, 135.0) | 73.0 (46.9,110.9) | 71.2 (40.6,103.1) | 78.0 (41, 158) |
| Missing(%) | 5 (0.58) | 1 (0.12) | 0 (0.0) | 26 (3.02) |
| Baseline height(cm) | ||||
| Median (range) | 173 (132,198) | 168 (145,192) | 165 (145,189) | 170 (148,200) |
| Missing (%) | 5 (0.58) | 1 (0.12) | 0 (0.0) | 27 (3.13) |
| Disease Duration (years) | ||||
| Median (range) | 0.33 (0.00, 3.0) | 2.40 (0.083,7.5) | 9.70 (0.250,30.0) | 0.33 (0.0,2.7) |
| Missing (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Years of education (years) | ||||
| Median (range) | NA | NA | NA | 11 (3, 24) |
| Missing (%) | 423 (49.1) | 114 (13.2) | 110 (12.8) | 0 (0.0) |
| Baseline MDS-UPDRS23 | ||||
| Median (range) | 27 (7,65) | 30 (2,100) | 39 (9,120) | 36 (9, 97) |
| Missing(%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| LRRK2 mutationa | ||||
| Yes (%) | 125 (14.50) | 98 (11.40) | 97 (11.30) | 0 (0.0) |
| No (%) | 298 (34.60) | 16 (1.86) | 13 (1.51) | 215 (24.90) |
| Concomitant medication | ||||
| Levodopa/Dopamine Agonists (%) | 386 (44.80) | 112 (13.00) | 1 (0.12) | 215 (24.90) |
| Other PD medication (%) | 37 (4.29) | 2 (0.23) | 109 (12.60) | 0 (0.0) |
Abbreviations: ICICLE = Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation, LRRK2 = Leucine-rich repeat kinase 2, MDS-UPDRS23 = Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part II plus Part III score, NA = not applicable, PD = Parkinson’s Disease, PPMI = Parkinson’s Progression Marker Initiative. In total, the analysis dataset composed to 862 number of subjects from which, 509 males, 353 females, 320 had LRRK2 mutation, 542 without LRRK2 mutation, 742 under Levodopa/Dopamine Agonists and 148 under other type of PD medication
LRRK2 = Yes consisted of subjects with at least one of the following LRRK2 mutations: p.R114C, p.R1441G, p.Y1699C, p.G2019S, rs76904798 and G2385R.